{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:01:26Z","timestamp":1777633286460,"version":"3.51.4"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,7,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Patients with cancer are at increased risk for Clostridium difficile\u2013associated diarrhea (CDAD). Little is known about treatment response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Two double-blind trials randomly allocated 1,105 patients with CDAD to fidaxomicin or vancomycin treatment (modified intent-to-treat [mITT]), and 183 of these had cancer. Univariate and multivariate post hoc analyses compared effects of treatment and patient characteristics on cure, recurrence, and sustained response after 4 weeks. Time to resolution of diarrhea (TTROD) was also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with cancer had a lower cure rate and longer TTROD than patients without cancer. Recurrence rates were similar. Cure was more likely with fidaxomicin than vancomycin (odds ratio [OR] 2.0; P = .065), recurrence was less likely (OR = 0.37; P = .018), and sustained response more frequent (OR = 2.56; P = .003). Under vancomycin, median TTROD was longer in patients with cancer than in those without (123 v 58 hours; log-rank P &lt; .001). With fidaxomicin, median TTROD was not significantly affected by presence of cancer (74 v 54 hours; log-rank P = .145). In the full mITT population, age, hypoalbuminemia, and cancer were inversely associated with clinical cure by multivariate analysis. Study treatment with vancomycin was a significant predictor of recurrence (P &lt; .001). Within the cancer population, low albumin was negatively and fidaxomicin was positively associated with improved cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For patients with cancer, fidaxomicin treatment was superior to vancomycin, resulting in higher cure and sustained response rates, shorter TTROD, and fewer recurrences.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2012.45.5899","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T06:45:06Z","timestamp":1369809906000},"page":"2493-2499","source":"Crossref","is-referenced-by-count":94,"title":["Resolution of<i>Clostridium difficile<\/i>\u2013Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin"],"prefix":"10.1200","volume":"31","author":[{"given":"Oliver A.","family":"Cornely","sequence":"first","affiliation":[{"name":"Oliver A. Cornely, University Hospital of Cologne and Zentrum f\u00fcr Klinische Studien K\u00f6ln\u2013BMBF 01KN1106, Cologne, Germany; Mark A. Miller, Jewish General Hospital, Montreal, Quebec, Canada; Bruno Fantin, University Paris Diderot, Paris, France; Kathleen Mullane, University of Chicago, Chicago, IL; Yin Kean and Sherwood Gorbach, Optimer Pharmaceuticals, San Diego, CA; and Sherwood Gorbach, Tufts University, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Oliver A. Cornely, University Hospital of Cologne and Zentrum f\u00fcr Klinische Studien K\u00f6ln\u2013BMBF 01KN1106, Cologne, Germany; Mark A. Miller, Jewish General Hospital, Montreal, Quebec, Canada; Bruno Fantin, University Paris Diderot, Paris, France; Kathleen Mullane, University of Chicago, Chicago, IL; Yin Kean and Sherwood Gorbach, Optimer Pharmaceuticals, San Diego, CA; and Sherwood Gorbach, Tufts University, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fantin","sequence":"additional","affiliation":[{"name":"Oliver A. Cornely, University Hospital of Cologne and Zentrum f\u00fcr Klinische Studien K\u00f6ln\u2013BMBF 01KN1106, Cologne, Germany; Mark A. Miller, Jewish General Hospital, Montreal, Quebec, Canada; Bruno Fantin, University Paris Diderot, Paris, France; Kathleen Mullane, University of Chicago, Chicago, IL; Yin Kean and Sherwood Gorbach, Optimer Pharmaceuticals, San Diego, CA; and Sherwood Gorbach, Tufts University, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Mullane","sequence":"additional","affiliation":[{"name":"Oliver A. Cornely, University Hospital of Cologne and Zentrum f\u00fcr Klinische Studien K\u00f6ln\u2013BMBF 01KN1106, Cologne, Germany; Mark A. Miller, Jewish General Hospital, Montreal, Quebec, Canada; Bruno Fantin, University Paris Diderot, Paris, France; Kathleen Mullane, University of Chicago, Chicago, IL; Yin Kean and Sherwood Gorbach, Optimer Pharmaceuticals, San Diego, CA; and Sherwood Gorbach, Tufts University, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Kean","sequence":"additional","affiliation":[{"name":"Oliver A. Cornely, University Hospital of Cologne and Zentrum f\u00fcr Klinische Studien K\u00f6ln\u2013BMBF 01KN1106, Cologne, Germany; Mark A. Miller, Jewish General Hospital, Montreal, Quebec, Canada; Bruno Fantin, University Paris Diderot, Paris, France; Kathleen Mullane, University of Chicago, Chicago, IL; Yin Kean and Sherwood Gorbach, Optimer Pharmaceuticals, San Diego, CA; and Sherwood Gorbach, Tufts University, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherwood","family":"Gorbach","sequence":"additional","affiliation":[{"name":"Oliver A. Cornely, University Hospital of Cologne and Zentrum f\u00fcr Klinische Studien K\u00f6ln\u2013BMBF 01KN1106, Cologne, Germany; Mark A. Miller, Jewish General Hospital, Montreal, Quebec, Canada; Bruno Fantin, University Paris Diderot, Paris, France; Kathleen Mullane, University of Chicago, Chicago, IL; Yin Kean and Sherwood Gorbach, Optimer Pharmaceuticals, San Diego, CA; and Sherwood Gorbach, Tufts University, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1086\/651706"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.9.877"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2010.01331.x"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.95"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023035"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.34.1011"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028654"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.1.109"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/138920009787048419"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000879"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.01035.x"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1758834009355164"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-89"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-7-24"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"B17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/j.1875-9114.1997.tb03072.x","volume":"17","author":"Jarvis B","year":"1997","journal-title":"Pharmacotherapy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400200139025"},{"key":"B19","author":"Masciullo V","journal-title":"Obstet Gynecol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2011.08.015"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.45.5899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T08:40:54Z","timestamp":1715416854000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.45.5899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,7,1]]}},"alternative-id":["10.1200\/JCO.2012.45.5899"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.45.5899","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}